Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery
- 1.4k Downloads
To formulate rifampicin, an anti-tuberculosis antibiotic, for aerosol delivery in a dry powder ‘porous nanoparticle-aggregate particle’ (PNAP) form suited for shelf stability, effective dispersibility and extended release with local lung and systemic drug delivery.
Rifampicin was encapsulated in PLGA nanoparticles by a solvent evaporation process, spray dried into PNAPs containing varying amounts of nanoparticles, and characterized for physical and aerosol properties. Pharmacokinetic studies were performed with formulations delivered to guinea pigs by intratracheal insufflation and compared to oral and intravenous delivery of rifampicin.
The PNAP formulations possessed properties suitable for efficient deposition in the lungs. In vitro release showed an initial burst of rifampicin, with the remainder available for release beyond eight hours. PNAPs delivered to guinea pigs by insufflation achieved systemic levels of rifampicin detected for six to eight hours. Moreover, rifampicin concentrations remained detectable in lung tissue and cells up to and beyond eight hours. Conversely, after pulmonary delivery of an aerosol without nanoparticles, rifampicin could not be detected in the lungs at eight hours.
Our results indicate that rifampicin can be formulated into an aggregated nanoparticle form that, once delivered to animals, achieves systemic exposure and extends levels of drug in the lungs.
KEY WORDSaerosols antibiotics nanoparticles pulmonary drug delivery tuberculosis
Fine particle fraction of the total dose less than 5.8 μm
Porous nanoparticle-aggregate particle
PNAPs containing 40% NP by weight
PNAPs containing 80% NP by weight
- 1.WHO. Tuberculosis fact sheet. Geneva: World Health Organization; 2006.Google Scholar
- 2.Riley RL, Mills CC, Nyka W, Weinstock N, Storey PB, Sultan LU, et al. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward. Am J Epidemiol 1959;70:185–96.Google Scholar
- 5.Thomas C. A literature review of the problems of delayed presentation for treatment and non-completion of treatment for tuberculosis in less developed countries and ways of addressing these problems using particular implementations of the DOTS strategy. J Manage Med 2002;16:371–400. doi:10.1108/02689230210446544.CrossRefGoogle Scholar
- 16.Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005;102:373–81. doi:10.1016/j.jconrel.2004.10.010.PubMedCrossRefGoogle Scholar
- 18.Dailey LA, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, et al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Control Release 2003;86:131–44. doi:10.1016/S0168-3659(02)00370-X.PubMedCrossRefGoogle Scholar
- 21.Saez A, Guzman M, Molpeceres J, Aberturas MR. Freeze-drying of polycaprolactone and poly(-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharma 2000;50:379–87. doi:10.1016/S0939-6411(00)00125-9.CrossRefGoogle Scholar
- 23.Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci U S A 2002;99. doi:10.1073/pnas.182233999.
- 32.Garcia-Contreras L, Hickey AJ. Pharmacokinetics of aerosolized rifampicin in the guinea pig. In: Dalby RN, Byron PR, Peart J, Farr S, editors. Respiratory drug delivery VIII. Raleigh, NC: Horwood; 2002.Google Scholar
- 45.Peloquin C, Vernon A. Antimycobacterial agents: rifamycins for mycobacterial infections. In: Yu V, Edwards G, McKinnon P, Peloquin C, Morse G, editors. Antimicrobial chemotherapy and vaccines, vol. II: antimicrobial agents. 2nd ed. Pittsburg: Esun Technologies; 2005. p. 383–402.Google Scholar
- 46.Peloquin C. Clinical pharmacology of the anti-tuberculosis drugs. In: Davies P, Barnes P, Gordon S, editors. Clinical tuberculosis. 4th ed. London: Hodder Arnold; 2008.Google Scholar